Fluicell AB - Asset Resilience Ratio

Latest as of September 2025: 6.04%

Fluicell AB (FLUI) has an Asset Resilience Ratio of 6.04% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Fluicell AB balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Skr990.00K

≈ $106.54K USD Cash + Short-term Investments

Total Assets

Skr16.38 Million

≈ $1.76 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Fluicell AB's Asset Resilience Ratio has changed over time. See FLUI net asset value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Fluicell AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Fluicell AB.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr990.00K	6.04%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr990.00K	6.04%

Asset Resilience Insights

Limited Liquidity: Fluicell AB maintains only 6.04% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Fluicell AB Industry Peers by Asset Resilience Ratio

Compare Fluicell AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	25.67%
Tubize-Fin BR:TUB	Biotechnology	0.05%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
Dashenlin Pharm Grp Co Ltd SHG:603233	Biotechnology	0.02%
Staidson Beijing Biopharma SHE:300204	Biotechnology	7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	41.25%
Ardelyx Inc NASDAQ:ARDX	Biotechnology	41.14%
Xiangxue Pharmaceutical SHE:300147	Biotechnology	0.05%

Annual Asset Resilience Ratio for Fluicell AB (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Fluicell AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	62.43%	Skr15.92 Million ≈ $1.71 Million	Skr25.51 Million ≈ $2.75 Million	+32.85pp
2023-12-31	29.58%	Skr2.76 Million ≈ $297.34K	Skr9.34 Million ≈ $1.01 Million	-47.41pp
2022-12-31	76.99%	Skr24.46 Million ≈ $2.63 Million	Skr31.77 Million ≈ $3.42 Million	+0.29pp
2021-12-31	76.70%	Skr20.69 Million ≈ $2.23 Million	Skr26.98 Million ≈ $2.90 Million	+0.98pp
2020-12-31	75.71%	Skr18.80 Million ≈ $2.02 Million	Skr24.83 Million ≈ $2.67 Million	+33.40pp
2019-12-31	42.32%	Skr8.44 Million ≈ $907.96K	Skr19.94 Million ≈ $2.15 Million	-43.27pp
2018-12-31	85.59%	Skr22.23 Million ≈ $2.39 Million	Skr25.97 Million ≈ $2.80 Million	+17.69pp
2017-12-31	67.91%	Skr7.83 Million ≈ $842.96K	Skr11.54 Million ≈ $1.24 Million	+28.30pp
2016-12-31	39.60%	Skr1.10 Million ≈ $118.27K	Skr2.77 Million ≈ $298.63K	--

pp = percentage points

About Fluicell AB

ST:FLUI Sweden Biotechnology

Market Cap

$2.11 Million

Skr19.58 Million SEK

Market Cap Rank

#29637 Global

#688 in Sweden

Share Price

Skr14.25

Change (1 day)

+6.34%

52-Week Range

Skr7.70 - Skr21.00

All Time High

Skr188.78